GAVI-documents

in page functions
 

28 November 2013

Final VIS analysis 2013: Rabies

Rabies Vaccine Investment Strategy November 2013 - Background document.

28 November 2013

Final VIS analysis 2013: Cholera

Cholera Vaccine investment strategy November 2013 - Background document.

28 November 2013

Final VIS analysis 2013: Yellow Fever

Yellow fever Vaccine investment strategy November 2013 - Background document.

28 November 2013

Summary consultations phase II [French]

VIS Phase II Consultation 2013.

28 November 2013

Summary consultations phase II

VIS Phase II Consultation 2013.

28 November 2013

Final VIS analysis 2013: Malaria

Malaria Vaccine investment strategy November 2013 - Background document.

28 November 2013

Final VIS analysis 2013: Maternal Influenza

Influenza Vaccine investment strategy November 2013 - Background document.

22 November 2013

VIS Independent Expert Committee

Independent Expert Committee for the Vaccine Investment Strategy.

24 October 2013

Definition of performance indicators for GAVI strategy 2011-2015

This GAVI Alliance Board paper, approved at the December 2010 Board meeting in Rwanda, lists goal-level indicators to monitor progress against GAVI's 2011-15 strategy.

11 October 2013

VIS prioritisation methodology

VIS phase I: vaccine and disease parameters assessed 1 Phase I Indicator Health impact Impact on child mortality U5 future deaths averted, 2015 – 2030 U5 future deaths averted per 100,000 vaccinated population Impact on overall mortality Total future deaths averted, 2015 – 2030 Total future deaths averted per 100,000 v

10 July 2013

Vaccine Investment Strategy 2013 Phase I - Vaccine Scorecards

VIS 2013 PHASE I 1. Procurement cost includes vaccine, syringe, safety box, and freight 2. Scoring based on cost per future death averted Cholera Phase I Scorecard Modelled scenario: periodic campaigns every 3 years targeting high risk 1-<15 year olds Category VIS Criteria Phase I Indicator Phase I Evaluation Health im

14 June 2013

Frequently asked questions about Gavi's co-financing

Frequently asked questions about co-financing.

07 June 2013

GAVI Business Plan 2013-2014: deliverables and activities

Strategic objective PO Programme objective Interim deliverable (2013) Interim deliverable (2014) Programme deliverables (2015) 2.3. Strengthen civil society engagement in the health sector 2.3.1 Promote active engagement of Civil Society Organisations (CSOs) At least 50% of countries, supported by partners, have active

29 May 2013

GAVI Business Plan 2013-2014: Background narrative

The GAVI Alliance Business Plan aims to support GAVI’s mission to save children’s lives and protect people’s health by improving access to immunisation in poor countries.

04 April 2013

GAVI-Government of China Hepatitis B vaccination programme - Evaluation Report

Evaluation of GAVI-Government of GAVI-Government of China Hepatitis B vaccination programme (2013, Abt Associates).

04 April 2013

GAVI-Government of China Hepatitis B vaccination programme - Management Response

The GAVI Secretariat’s management response to the evaluation of GAVI-Government of China Hepatitis B vaccination programme (2012, Abt Associates).

26 March 2013

Request form for emergency response

As outlined in the GAVI policy on fragility and immunisation, GAVI will provide one-off flexibilities in order to help protect immunisation systems and existing GAVI support in countries experiencing time-limited emergencies. This form is developed to assist countries in such emergency circumstances wanting to apply for these flexibilities.

22 March 2013

CSO Implementation and Results Framework

The GAVI Board has decided that HSS will be the single window for GAVI cash grants. GAVI support for CSOs will be part of a country Health Systems Strengthening (HSS) proposal to improve immunisation outcomes. The document presents why and how GAVI works with and supports CSOs in programme implementation.

18 March 2013

GAVI Gender Policy Evaluation Report with Annexes

EVALUATION OF GAVI GENDER POLICY FINAL REPORT 14 December 2012 Submitted to: GAVI Alliance 2, Chemin des Mines 1211, Geneva 2 Switzerland Submitted by: ICF Macro, Inc. 11785 Beltsville Drive, Suite 300 Calverton, MD 20705 USAi TABLE OF CONTENTS Table of Contents i Acronyms and Abbreviations iii Executive Summary iv Key

18 March 2013

GAVI Gender Policy Recommendations Report

EVALUATION OF GAVI GENDER POLICY KEY RECOMMENDATIONS 14 December 2012 Submitted to: GAVI Alliance 2, Chemin des Mines 1211, Geneva 2 Switzerland Submitted by: ICF Macro, Inc. 11785 Beltsville Drive, Suite 300 Calverton, MD 20705 USA1 INTRODUCTION The GAVI Alliance public-private partnership brings together key stakehol

18 March 2013

GAVI Gender Policy Evaluation Management Action Plan

MANAGEMENT ACTION PLAN – EVALUATION OF THE GAVI ALLIANCE GENDER POLICY Date: 28 February 2013 1 Theme Recommendation Management Action Timeline/Responsibility Rationale, Design and Planning 1 Revision to gender policy: update rationale, strategic directions and commitments GAVI should commence a Gender Policy revision

06 March 2013

AMC Process and Design Evaluation Full Report

1 The Advance Market Commitment for Pneumococcal Vaccines Process and Design Evaluation Full Report February 15, 2013 Contents Preface ..................................................................................................................................................... 3 Acronyms and Abbreviations ......

06 March 2013

AMC Process and Design Evaluation Mgt Response

Page 1 of 2 GAVI Secretariat Management Response to the Process and Design Evaluation of the Pilot Advance Market Commitment for Pneumococcal Vaccines Advance Market Commitments (AMCs) for vaccines aim to encourage the development and production of affordable vaccines tailored to the needs of developing countries. Foll

06 March 2013

AMC Process and Design Evaluation Appendix Feb 2013

The Advance Market Commitment for Pneumococcal Vaccines Process and Design Evaluation Appendix February 15, 2013 Contents Appendix ............................................................................................................................................ 2 Appendix I. Timelines and inputs to design pro

 



close icon

modal window here